Opus Genetics COO awarded 250,000 RSUs

Opus Genetics, Inc. reported that its Chief Operating Officer, Joseph K. Schachle, received a grant of 250,000 shares of common stock in the form of restricted stock units on 01/22/2026.

Rhea-AI Filing Summary

Opus Genetics, Inc. reported that its Chief Operating Officer, Joseph K. Schachle, received a grant of 250,000 shares of common stock in the form of restricted stock units on 01/22/2026. These RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, conditioned on his continuing service with the company. The grant was recorded at a price of $0 per share, reflecting that no cash payment is required from him for the award. Following this transaction, he beneficially owns 304,500 shares of Opus Genetics common stock, held directly.

Insider Trade Summary

Grant/Award: 250,000 shares

Grant/Award 1 txn

Insider SCHACHLE JOSEPH K

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	250,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 304,500 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Opus Genetics (IRD) report for its COO?

Opus Genetics reported that Chief Operating Officer Joseph K. Schachle received a grant of 250,000 restricted stock units of common stock on 01/22/2026.

How do the 250,000 RSUs granted to the Opus Genetics COO vest?

The 250,000 RSUs vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen quarters, subject to his continuing service.

Did the Opus Genetics COO pay for the 250,000-share RSU grant?

No. The Form 4 shows the transaction price per share as $0, meaning the restricted stock units were granted without a cash purchase price.

How many Opus Genetics (IRD) shares does the COO own after this grant?

After the reported RSU grant, Chief Operating Officer Joseph K. Schachle beneficially owns 304,500 shares of Opus Genetics common stock, held directly.

What does this Form 4 filing indicate about insider ownership at Opus Genetics?

The filing indicates that an Opus Genetics executive officer, the Chief Operating Officer, has received a significant equity-based award, increasing his direct beneficial ownership to 304,500 shares.

Who signed the Opus Genetics (IRD) Form 4 reporting this RSU grant?

The Form 4 was signed by /s/ Amy Rabourn, by Power of Attorney, on behalf of the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/26/2026 - 07:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHACHLE JOSEPH K

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		A		250,000(1)	A	$0	304,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units which vest in substantially equal quarterly installments on the anniversary of the grant date over the next sixteen (16) quarters, subject to the Reporting Person's continuing service.

	/s/ Amy Rabourn, by Power of Attorney	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.